Acute hemodynamic changes during far infrared treatment of the arteriovenous fistula in hemodialysis patients

September 1, 2023

Abstract

Background: The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis (HD) treatment and

preservation of a stable vascular access is crucial. Long term Far Infrared Radiation (FIR) has been found to increase

access flow together with an enhanced maturation and patency of the AVF. The acute effects of FIR on access flow have

been sparsely described and the results are contradictory, perhaps due to differences in measurement conditions and

other factors of importance for access flow.

Methods: Twenty patients in HD with an AVF were included. Each patient was randomized to receive either FIR

(FIR group) or no FIR (control group). The acute changes in access flow were investigated in both groups on the

second dialysis day of the week and during the first 1.5 h of the dialysis session. Concomitant changes in hemodynamic

parameters of importance for access flow were also explored.

Results: There was no significant change in access flow in the FIR group compared with the control group (median

(Interquartile Range)) (−10 (−413.8; 21.3) ml/min vs −17.5 (−83.8; 76.3) ml/min, p = 0.58). There was no significant

difference in any of the hemodynamic parameters between the FIR and the control group; cardiac output (−0.7 (−1.2;

−0.2) l/min vs −0.4 (−0.9; 0.1) l/min, p = 0.58), cardiac index (−0.3 (−0.5; −0.1)) l/min/m2 vs −0.3 (−0.4; 0) l/min/m2, p = 0.68),

mean arterial pressure (5.5 (−1.8; 8.4) mmHg vs 1.5 (−3; 6.3) mmHg, p = 0.35) and total peripheral resistance (2 (1.8; 3.4)

mmHg × min/l vs 1 (−0.3; 3.1) mmHg × min/l, p = 0.12).

Conclusion: In this trial, with a highly standardized set-up, one session of FIR did not result in any acute changes in

access flow. This was not due to differences in the hemodynamic parameters between the groups.

-J Vasc Access. 2023 Jul;24(4):739-746.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
May 23, 2025
We’re excited to announce that FIRAPY will be exhibiting at the 62nd ERA Congress in Vienna from June 4–7, 2025 ! 📍 Booth No.: X1.200 📅 June 4–7, 2025 📍 Austria Center Vienna This marks FIRAPY’s first European event since the COVID-19 pandemic , making it a special occasion for us to reconnect with partners and professionals across the continent. This year’s congress theme, “Game Changers in Nephrology,” aligns perfectly with FIRAPY’s mission to enhance dialysis care through innovative vascular access management. We look forward to seeing old friends and new collaborators who share our commitment to improving outcomes for dialysis patients. Whether you're already using FIRAPY or exploring its clinical potential, we warmly invite you to visit our booth and connect with our team.  Let’s explore how far-infrared therapy is transforming the future of vascular access—together.
May 23, 2025
From February 28 to March 1, FIRAPY was honored to participate in Dialysis Weekend 2024 in Pattaya, Thailand, at the invitation of our valued partner K2 Thailand . This annual event, hosted by the Nephrology Society of Thailand ( event site ), is a key gathering for nephrology professionals across the country. This occasion marked a milestone for K2 Thailand, as their entire dialysis sales team made their first collective public appearance alongside FIRAPY. The team’s strong presence and professionalism drew significant attention from both clinicians and industry attendees, highlighting the growing interest in FIRAPY's role in dialysis care. A special highlight of the event was the visit from Dr. Suki , a well-known figure in the international nephrology community ( WCN profile ). Dr. Suki stopped by the K2 booth to personally show support and encouragement to the team, reinforcing the collaboration and shared mission of improving vascular access outcomes for dialysis patients. 
December 2, 2024
Meet FIRAPY at Booth i1115a!
More Posts